Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Salarius Pharmaceuticals Inc (SLRX)

Salarius Pharmaceuticals Inc (SLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,114
  • Shares Outstanding, K 4,314
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,540 K
  • 60-Month Beta 1.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.37
Trade SLRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.53
  • Most Recent Earnings $-0.22 on 03/22/24
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.15
  • Number of Estimates 1
  • High Estimate -1.15
  • Low Estimate -1.15
  • Prior Year -2.23
  • Growth Rate Est. (year over year) +48.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4303 +12.71%
on 03/27/24
0.7888 -38.51%
on 03/01/24
-0.1348 (-21.75%)
since 02/27/24
3-Month
0.4303 +12.71%
on 03/27/24
0.7914 -38.72%
on 01/12/24
-0.0765 (-13.62%)
since 12/27/23
52-Week
0.4303 +12.71%
on 03/27/24
2.6800 -81.90%
on 04/19/23
-1.5950 (-76.68%)
since 03/27/23

Most Recent Stories

More News
Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Multiple development and data milestones expected from seclidemstat and SP-3164 programs in 2H22 Conference call and webcast today at 11:00 a.m. ET...

SLRX : 0.4850 (-1.02%)
Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Clinical Trial Now Expands to Fifteen U.S. Trial Sites ...

SLRX : 0.4850 (-1.02%)
Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement

HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies...

SLRX : 0.4850 (-1.02%)
VNRX : 0.7430 (-0.91%)
Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022

Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET...

SLRX : 0.4850 (-1.02%)
Salarius Pharmaceuticals to Participate in BIO International Convention 2022

HOUSTON, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing...

SLRX : 0.4850 (-1.02%)
Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential...

SLRX : 0.4850 (-1.02%)
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results

Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA Advancing multiple drug development programs, led by SP-3164 in targeted protein...

SLRX : 0.4850 (-1.02%)
Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius planning for SP-3164 IND Application Submission in 2023...

SLRX : 0.4850 (-1.02%)
Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress

Conference Call and Live Audio Webcast Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET...

SLRX : 0.4850 (-1.02%)
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering

HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing cancer...

SLRX : 0.4850 (-1.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Salarius Pharmaceuticals Inc. is a clinical-stage oncology company. It develops therapies for the treatment of cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and...

See More

Key Turning Points

3rd Resistance Point 0.6661
2nd Resistance Point 0.6080
1st Resistance Point 0.5465
Last Price 0.4850
1st Support Level 0.4269
2nd Support Level 0.3688
3rd Support Level 0.3073

See More

52-Week High 2.6800
Fibonacci 61.8% 1.8206
Fibonacci 50% 1.5552
Fibonacci 38.2% 1.2897
Last Price 0.4850
52-Week Low 0.4303

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar